Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014

Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3,
                                     2014

PR Newswire

AUSTIN, Texas, Jan. 14, 2014

AUSTIN, Texas, Jan. 14, 2014 /PRNewswire/ --Luminex Corporation (Nasdaq:
LMNX) today announced that it expects to report results for the fourth quarter
of 2013 on Monday, February 3, 2014. A press release announcing the results is
scheduled for release after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and
financial results for the fourth quarter and twelve months ended December 31,
2013 on February 3, 2014, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide
presentation, both of which may be accessed at Luminex Corporation's website
at http://www.luminexcorp.com. Simply log on to the website, go to the About
Us section and access the Investor Relations link. Please go to the website at
least 15 minutes prior to the call to register, download and install any
necessary audio/video software. If you are unable to participate during the
live webcast, the call and slides will be archived for six months on the
website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.
If you use this software, press and hold the CTRL key when you click on the
Register button. Please contact your IT group if you are unable to override
this feature. Unauthorized recording or downloading of this event is not
permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing
healthcare and research worldwide. The Company is transforming global
healthcare and life-science research through the development, manufacturing
and marketing of proprietary instruments and assays utilizing xMAP^®
open-architecture, multi-analyte platform and MultiCode^® real-time polymerase
chain reaction (PCR) and multiplex PCR-based technologies, that deliver
cost-effective and rapid results to clinicians and researchers. Luminex's
technology is commercially available worldwide and in use in leading clinical
laboratories as well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. The Company is meeting the needs of customers in
markets as diverse as clinical diagnostics, pharmaceutical drug discovery,
biomedical research including genomic and proteomic research, personalized
medicine, bio-defense research and food safety. For further information on
Luminex Corporation and the latest advances in multiplexing using award
winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or
management's intentions, plans, beliefs, expectations or predictions of future
events are forward-looking statements. The words "believe," "expect,"
"intend," "estimate," "anticipate," "will," "could," "should" and similar
expressions are intended to further identify such forward-looking statements
for purposes of the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company's actual results or performance could
differ materially from those anticipated or projected in such forward-looking
statements. Factors that could cause Luminex's actual results or performance
to differ materially include risks and uncertainties relating to, among
others, market demand and acceptance of Luminex's products, the Company's
dependence on strategic partners for development, commercialization and
distribution of products, concentration of the Company's revenue in a limited
number of strategic partners, fluctuations in quarterly results due to a
lengthy and unpredictable sales cycle and bulk purchases of consumables,
Luminex's ability to scale manufacturing operations and manage operating
expenses, gross margins and inventory levels, potential shortages of
components, competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's strategic
operating plans, risks and uncertainties associated with implementing our
acquisition strategy and the ability to integrate acquired companies or
selected assets into our consolidated business operations, as well as the
risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms
10-K and 10-Q, as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment of Luminex
as of the date of this press release, and Luminex expressly disclaims any
intent, obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements to reflect any change in Luminex's
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statements are based.

Luminex Corporate Contact:
Harriss Currie, 512.219.8020
Sr. Vice President, Finance and CFO
hcurrie@luminexcorp.com

Luminex Investor Contact:
Matthew Norman, 512.219.8020
Government and Investor Relations Manager
mnorman@luminexcorp.com

SOURCE Luminex Corporation

Website: http://www.luminexcorp.com
 
Press spacebar to pause and continue. Press esc to stop.